Hereditary Cancer Panel denied as duplicate or overlapping therapy by Carelon (formerly AIM)?

NCCN-aligned for hereditary cancer testing. Pre-test genetic counseling required for many panels. Avalon overlap in some plans.

GC by ABGC-certified counselor (telegenetics qualifies). NCCN BOP/COL footnotes endorse multi-gene panels when >1 syndrome on differential. Reroute to in-network lab if denial is contractual.

## Why Carelon Denied Your Hereditary Cancer Panel as Duplicate Therapy

Carelon (formerly AIM Specialty Health) manages genetic testing benefits on behalf of many health plans. A "duplicate therapy" denial on a hereditary cancer panel typically means the insurer's records indicate that equivalent genetic testing has already been performed — either a prior multi-gene panel, a single-gene test covering overlapping genes, or a test performed under a different claim. This denial is frequently wrong or misapplied, and it is absolutely worth appealing.

## Why This Denial Is Appealable

Genetic panels are not interchangeable. A prior test covering one or two genes is clinically distinct from a comprehensive multi-gene hereditary cancer panel. Laboratories use different sequencing platforms, variant-classification pipelines, and gene sets. Clinically, results from an earlier, narrower test do not substitute for a broader panel when your clinician has documented a specific indication. Carelon's own coverage policies distinguish between prior testing scope and current clinical need — your appeal should force that distinction into the record.

## Federal Appeal Framework

• Internal Appeal: Under the ACA and ERISA §503, you have the right to a full-and-fair internal appeal. Submit within the deadline stated on your denial letter (typically 180 days from the denial date for ERISA plans).
• External Review: If the internal appeal is denied, ACA §2719 entitles most members to an independent external review by an accredited Independent Review Organization (IRO). The external-review window is generally within four months of the final internal denial. For urgent clinical situations, an expedited external review (often resolved within 72 hours) is available.
• ERISA Plans: If your coverage is through an employer self-funded plan, ERISA §503 governs. Request the full claims file and Summary Plan Description before your internal appeal.

## Concrete Appeal Steps and Timeline

1. Request the denial rationale in writing — obtain the specific clinical criteria Carelon applied and identify exactly which prior test they consider a "duplicate." 2. Pull the prior test report — document the gene set tested, the laboratory, the date, and the methodology. 3. File internal appeal — typically within 180 days; confirm your plan's deadline. 4. File external review — if internal appeal fails, file promptly (within ~four months of final denial).

## Documentation to Gather

• Complete report from any prior genetic test, including the exact genes analyzed
• Prescriber letter explaining why the current panel is clinically distinct from prior testing (different gene set, updated variant classifications, new family history information, or guideline-driven re-testing criteria)
• Pathology or clinical records confirming the current diagnosis or elevated-risk indication
• Relevant guideline language from the applicable professional organization (such as NCCN) supporting the specific panel ordered — obtain the current version directly from that organization

## Criteria-Mapping Structure

For each requirement in Carelon's coverage policy, document the specific chart fact that satisfies it:

| Policy Requirement | Your Supporting Evidence | |---|---| | No equivalent prior test on file | Prior test report showing different gene set or older platform | | Current clinical indication documented | Diagnosis confirmation, family history update, or new guideline criterion | | Ordering provider attests to medical necessity | Prescriber letter addressing the specific gap in prior testing |

Match every listed criterion to a specific document in your chart. Gaps in this table are what Carelon will use to uphold the denial.